N
Noemi Reguart
Researcher at The Breast Cancer Research Foundation
Publications - 141
Citations - 13136
Noemi Reguart is an academic researcher from The Breast Cancer Research Foundation. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 39, co-authored 113 publications receiving 11574 citations. Previous affiliations of Noemi Reguart include Gen-Probe Incorporated & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Cmet-22. capmatinib (inc280) in metδex14-mutated advanced non-small cell lung cancer (nsclc): efficacy data from the phase 2 geometry mono-1 study
Rebecca S. Heist,Takashi Seto,Ji-Youn Han,Noemi Reguart,Edward B. Garon,Harry J.M. Groen,Daniel Shao-Weng Tan,Toyoaki Hida,Maja J.A. de Jonge,Sergey Orlov,Egbert F. Smit,Pierre-Jean Souquet,Johan Vansteenkiste,Sylvie Le Mouhaer,Anna Robeva,M. Waldron-Lynch,Monica Giovannini,Juergen Wolf +17 more
TL;DR: These data confirm capmatinib to be a promising new treatment option for patients with METΔex14-mutated advanced NSCLC regardless of line of therapy, with deep and durable responses including in patients with brain metastases, and a manageable toxicity profile.
Journal ArticleDOI
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Roxana Reyes,Clara Mayo-de-las-Casas,Cristina Teixidó,Carlos Cabrera,Elba Marin,Ivan Vollmer,Pedro Jares,Mónica Garzón,Miguel Angel Molina-Vila,Noemi Reguart +9 more
Journal ArticleDOI
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Salma K. Jabbour,Ki Hyeong Lee,Nicolaj Frost,Valeriy Breder,Dariusz M. Kowalski,Issam Abdelkarim Alawin,Evgeny Levchenko,Noemi Reguart,Alex Martinez-Marti,Baerin Houghton,Jean-Baptiste Paoli,Sufia Safina,Keunchil Park,Takefumi Komiya,Amy Sanford,Vishal Boolell,Hong Liu,A. Samkari,Steven M. Keller,Martin Reck +19 more
TL;DR: Pembro plus cCRT continues to demonstrate promising antitumor activity, regardless of PD-L1 TPS and tumor histology, and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC with longer follow-up.
Journal ArticleDOI
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
Estela Sánchez-Herrero,Roberto Serna-Blasco,Vadym Ivanchuk,Rosario García-Campelo,Manuel Dómine Gomez,Jose Miguel Sanchez,Bartomeu Massuti,Noemi Reguart,Carlos Camps,Sandra Sanz-Moreno,Silvia Calabuig-Fariñas,Eloisa Jantus-Lewintre,Magdalena Arnal,Dietmar Fernández‐Orth,Virginia Calvo,Víctor González‐Rumayor,Mariano Provencio,Atocha Romero +17 more
TL;DR: In this paper, the authors evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next-generation sequencing (NGS) upon disease progression in nonsmall cell lung cancer (NSCLC) patients.
Journal Article
The promise of pharmacogenomics: Gemcitabine and pemetrexed
Rafael Rosell,Miquel Taron,Jose Miguel Sanchez,Teresa Moran,Noemi Reguart,Benjamin Besse,Dolores Isla,Bartomeu Massuti,Vicente Alberola,Jose Javier Sanchez +9 more
TL;DR: Accumulated data indicate that overexpression of genes involved in cancer glycolysis pathways plays an important role, and might be an independent mechanism of chemoresistance, and one can envision that substantial improvements in therapeutic outcome could benefit from the integration of tailored ribonucleotide reductase-dependent chemotherapy, ribon nucleotide reduCTase antisense therapy, and targeted therapy.